The biotech's CEO says the clinical trial is the first to show that it is possible to usher large-molecule drugs across the blood-brain barrier.

After fluffing its lines in two mid-to-late stage trials in lung and colorectal cancer over the past few years, Daiichi and ArQule had hoped that tivantinib…

Arix Biosciences has made good on its promise to raise £100 million ($127 million) in its public offering on the London Stock Exchange as it looks to put the…

Takeda and TiGenix have presented 52-week data on their stem cells in Crohn’s disease patients with treatment-refractory complex perianal fistulas.

uniQure plans to start a three-pronged clinical trial program next year as key assets from its in-house pipeline and Bristol-Myers Squibb collaboration advance…

Prima Biomed has pushed the accelerator on its in-house drug development program, pressing ahead with two trials of its immuno-oncology drug IMP321 in breast…

Merck has taken a big step toward getting its lead HIV candidate doravirine to market, setting up a context with J&J's big-selling Prezista.

VC Versant has pumped $20 million on its own into its newly launched preclinical liver disease upstart Jecure, with its founders coming out from a former…

Ardelyx has hit its primary endpoint for its key asset tenapanor in a phase 3 hyperphosphatemia test—a much needed positive after years of trial setbacks.

R&D